Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

RDEA3170 Tablet and Capsule Bioavailability Study

17 november 2017 uppdaterad av: Ardea Biosciences, Inc.

A Phase 1, Randomized, Open-Label, Study in Healthy Adult Male Subjects to Assess the Relative Bioavailability and Food Effect of Various Formulations of RDEA3170

The purpose of this study is to determine the relative bioavailability of RDEA3170 capsules compared with RDEA3170 tablets.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Faktisk)

35

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Manlig

Beskrivning

Inclusion Criteria:

  • Subject is able to understand the study procedures and the risks involved, and is willing to provide written informed consent before the first study-related activity.
  • Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40 kg/m2.
  • Subject has a Screening serum urate level of 4 to 7 mg/dL.
  • Subject is free of any clinically significant disease or medical condition, per the Investigator's judgment.

Exclusion Criteria:

  • Subject has a history or suspicion of kidney stones.
  • Subject has undergone major surgery within 3 months prior to Screening.
  • Subject donated blood or experienced significant blood loss within 12 weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to Day 1.
  • Subject has clinically unacceptable physical examination, per the Investigator's judgment.
  • Subject has clinically relevant abnormalities in blood pressure, heart rate, or body temperature, per the Investigator's judgment.
  • Subject has Screening clinical safety laboratory parameters (serum chemistry [other than serum creatinine and serum urate], hematology, coagulation or urinalysis) that are outside the normal limits and are considered clinically significant by the Investigator.
  • Subject has a serum creatinine value above the upper limit of normal at the Screening visit.
  • Subject has clinically relevant abnormalities in 12-lead electrocardiogram, per the Investigator's judgment.
  • Subject has a history of cardiac abnormalities
  • Subject cannot swallow multiple tablets or capsules.
  • Subject has received any strong or moderate enzyme-inducing drug or product within 2 months prior to Day 1.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Grundläggande vetenskap
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Treatment A
RDEA3170, 5 mg (FN24), administered in the fasted state.
Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
Andra namn:
  • Kohort 1
Experimentell: Treatment B
RDEA3170, 5 mg (FN24), administered in the fed state (high-fat, high-calorie meal).
Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
Andra namn:
  • Kohort 1
Experimentell: Treatment C
RDEA3170, 10 mg (FN25), administered in the fasted state.
Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
Andra namn:
  • Kohort 1
Experimentell: Treatment D
RDEA3170, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal).
Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
Andra namn:
  • Kohort 1
Experimentell: Treatment E
RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
Andra namn:
  • Kohort 1
Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
Andra namn:
  • Kohort 3
Experimentell: Treatment I
RDEA3170, 10 mg (FN26), administered in the fasted state.
Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
Andra namn:
  • Kohort 3
Experimentell: Treatment J
RDEA3170, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).
Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
Andra namn:
  • Kohort 3
Experimentell: Treatment K
RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
Andra namn:
  • Kohort 1
Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
Andra namn:
  • Kohort 3

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Maximum Observed Plasma Concentration (Cmax)
Tidsram: Day 1, 5, 9, 13, 17
Cmax is the maximum observed concentration of a drug after administration
Day 1, 5, 9, 13, 17
Time of Occurrence of Maximum Observed Concentration (Tmax)
Tidsram: Day 1, 5, 9, 13, 17
Tmax is the time of occurrence of cmax
Day 1, 5, 9, 13, 17
Area Under the Concentration-time Curve From Time Zero to the Quantifiable Last Sampling Timepoint (AUC Last)
Tidsram: Day 1, 5, 9, 13, 17
AUC last is the area under the plasma concentration time curve from zero to the last quantifiable sampling timepoint
Day 1, 5, 9, 13, 17
Area Under the Concentration-time Curve From 0 to Infinity (AUC∞)
Tidsram: Day 1, 5, 9, 13, 17
AUC 0-∞ is a meausre of total concentration from time zero to infinity
Day 1, 5, 9, 13, 17
Apparent Terminal Half-life (t1/2)
Tidsram: Day 1, 5, 9, 13, 17
t1/2 is a measure of apparent terminal half-life
Day 1, 5, 9, 13, 17
Maximum Observed Plasma Concentration (Cmax): Effect of High Fat Meal on the PK of RDEA3170 Capsules
Tidsram: Day 1, 5, 9, 13, 17
Cmax is the maximum observed concentration of a drug after administration
Day 1, 5, 9, 13, 17
AUC Last: Effect of High Fat Meal on the PK of RDEA3170 Capsules
Tidsram: Day 1, 5, 9, 13, 17
AUC last is the area under the plasma concentration time curve from zero to the last quantifiable sampling timepoint
Day 1, 5, 9, 13, 17
AUC∞: Effect of High Fat Meal on the PK of RDEA3170 Capsules
Tidsram: Day 1, 5, 9, 13, 17
AUC 0-∞ is a meausre of total concentration from time zero to infinity
Day 1, 5, 9, 13, 17

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pharmacodynamics (PD) Profile of RDEA3170
Tidsram: Day -1, 1, 5, 9, 13, 17
Serum samples were collected at the following timepoints in relation to RDEA3170 dosing: Day 1 (Cohort 1 and Cohort 3): -24, -23, -22, -21, -20, -18, -16, -14, and -12 hours prior to dosing. Days 1, 5, and 9 (Cohort 1 and Cohort 3), and Days 13 and 17 (Cohort 1 only): predose (within 30 minutes prior to dosing) and 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose. Urine samples (total catch) were collected at the following timepoints in relation to RDEA3170 dosing: Day 1 (Cohort 1 and Cohort 3): -24 to -21, -21 to -18, -18 to -12, and -12 to 0 hours predose. Days 1, 5, and 9 (Cohort 1 and Cohort 3), and Days 13 and 17 (Cohort 1 only): 0 to 3, 3 to 6, 6 to 12, and 12 to 24 hours postdose.
Day -1, 1, 5, 9, 13, 17
Incidence of Treatment-Emergent Adverse Events
Tidsram: 8 weeks
8 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Studierektor: J Hall, MD, Ardea Biosciences, Inc.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 maj 2015

Primärt slutförande (Faktisk)

26 juni 2015

Avslutad studie (Faktisk)

29 januari 2016

Studieregistreringsdatum

Först inskickad

30 april 2015

Först inskickad som uppfyllde QC-kriterierna

15 maj 2015

Första postat (Uppskatta)

19 maj 2015

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

20 augusti 2018

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 november 2017

Senast verifierad

1 november 2017

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • RDEA3170-111

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .